A RANDOMIZED CONTROLLED PHASE 3 TRIAL OF RESMETIROM IN NONALCOHOLIC STEATOHEPATITIS: 52-WEEK DATA FROM MAESTRO-NASH

Jörn Schattenberg  1     Pierre Bedossa  2     Cynthia D. Guy  3     Rohit Loomba  4     Rebecca Taub  5     Dominic Labriola  5     Sam E. Moussa  6     Guy W. Neff  7     Arun J Sanyal  8     Mazen Noureddin  9     Meena Bansal  10     Naim Alkhouri  11     Vlad Ratziu  12     Stephen A. Harrison  13    
1 Universitätsmedizin Mainz, Mainz, Germany
2 Université Paris-Diderot Hopital Beaujon, Paria, France
3 Duke University Medical Center, Durham, United States
4 University of California San Diego, San Diego, United States
5 Madrigal Pharmaceuticals, Conshohocken, United States
6 University of Arizona for Medical Sciences, Tucson, United States
7 Covenant Metabolic Specialists, Sarasota, United States
8 Virginia Commonwealth University School of Medicine, Richmond, United States
9 Cedars-Sinai Medical Center, Los Angeles, United States
10 Mt Sinai, New York, United States
11 Arizona Liver Health, Tucson, United States
12 Hôpital Pitié Salpêtrière, Paris, France
13 Pinnacle Clinical Research, San Antonio, United States

Topic
Hepatobiliary

Session
Opening Plenary

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing